Business
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral present
About this update from Nurix Therapeutics, Inc.
[{"type":"image","alt":"Nurix Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Nurix Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":124,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/d4426df492fc50ab857f27928363f9ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GUPiZSd9EAPs2S1gR73bqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d4426df492fc50ab857f27928363f9ff","width":124,"height":59},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/GUPiZSd9EAPs2S1gR73bqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d4426df492fc50ab857f27928363f9ff","width":124,"height":59}},"lazy":false},{"type":"text","content":"BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden.","length":629,"tagName":"p"},{"type":"text","content":"Oral Presentation Details: ","length":26,"tagName":"p"},{"type":"text","content":"Title: Updated efficacy and safety data from an ongoing phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL across lines of therapyPresenter: Tahla Munir, MBChB, Ph.D.Session title: s449 Novel therapies in relapsed/refractory CLLSession date and time: June 14, 2026, 11:00 – 12:15 CEST Session Room: A10-11 HallAbstract ID: S150","length":362,"tagName":"p"},{"type":"text","content":"About Bexobrutideg (NX-5948)Bexobrutideg is an investigational, orally bioavailable, brain penetrant, highly selective small molecule degrader of Bruton’s tyrosine kinase (BTK) currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory CLL. Nurix also continues enrollment in the NX-5948-301 Phase 1a/1b clin...